ADCT Adc Therapeutics SA
Health Care, filed as ADC THERAPEUTICS SA (SHS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
Bought by 1 manager in 2026 Q3, sold by 1
In 2026 Q3 James Silverman added to Adc Therapeutics, while Nathan Fischel trimmed.
Who owns this now
Largest portfolio weights among holders, up to 0.6% (James Silverman, Opaleye Management). Not free-float ownership.
Who owns ADCT
Sorted by value, long equity only, as of 2026 Q3.
| History | |||||
|---|---|---|---|---|---|
| James Silverman, Opaleye Management | Add +481.5% | 4,070,819 | $5M | History | |
| Nathan Fischel, DAFNA Capital Management | Reduce −25.9% | 57,081 | $70K | History |
Insider trades
Open-market buys and sales by ADCT's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $19.6M sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Redmile Group, LLC 10% owner, +2 joint filersSale$19.6M 5,880,415 shares at $3.34Traded Mar 31–Apr 2 Filed Apr 2
Also filed in the last 12 months, not counted as buying or selling: 17 share withholdings for taxes and 16 stock grants.
Congress
No member of Congress reported trading ADCT in the last three years. 1 member listed it in 2025 annual reports.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 424B3 | FORM 424B3 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 2.02,7.01,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 1.01,2.02,3.02,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 5.07,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | FORM DEFA14A | Filing Doc | |
| 424B3 | FORM 424B3 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 424B3 | FORM 424B3 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total current assets | $336.29M | $307.39M | $306.34M |
| Total non-current assets * | $18.49M | $14.59M | $16.82M |
| Total assets | $354.78M | $321.98M | $323.15M |
| Total current liabilities | $67.67M | $80.47M | $70.16M |
| Total non-current liabilities * | $435.36M | $444.15M | $438.82M |
| Total equity | -$148.25M | -$202.64M | -$185.83M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon